Diagnostics M&A Deals Skyrocket in 2021 as Companies Have COVID-19 Cash to Burn
As many diagnostics companies continued to benefit from high volumes of COVID-19testing, cash burned a hole in the pockets of many in the industry, and major players and smaller newbies alike picked up new businesses.
Diagnostics M&A Deals Skyrocket in 2021 as Companies Have COVID-19 Cash to Burn
Published in 360Dx
Author: Kelsy Ketchum
Abstract:
As many diagnostics companies continued to benefit from high volumes of COVID-19testing, cash burned a hole in the pockets of many in the industry, and major players and smaller newbies alike picked up new businesses.
News
Outcome Capital Announces Partnership of ZIEN Medical and Averra Holdings
Outcome Capital served as exclusive strategic and financial advisor to ZIEN
Read MoreResources
Outcome Capital Life Science Market Pulse, May 2025
Outcome Capital Life Science Market Pulse May 2025 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2025. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Outcome Capital and Outcome Life Sciences are affiliates of Outcome Holdings, LLC
Business Continuity Plan | Privacy Policy | Regulation Best Interest
